GAD1 and nervous system disorder: As the cumulative prevalence of those antibodies—as reported by the large scale study of Dahm et al.—in a ‘neurological disease population’ (0.5% for anti-GAD and ≤ 0.1% for the other Ab) is clearly lower than seen in our cohort, the percentage of patients with anti-GAD or group II Ab might be enriched in a cohort of patients having an atypical IIF pattern on primate cerebellar slices [22].